riluzole 5 MG/ML Oral Suspension [Tiglutik]

What the CMS Formulary Data Shows for riluzole 5 MG/ML Oral Suspension [Tiglutik]

Per the CMS 2026 Part D formulary file, riluzole 5 MG/ML Oral Suspension [Tiglutik] (RxNorm concept RXCUI 2059266, generic name riluzole) appears on 19 distinct formulary files spanning 106 Medicare Part D plan offerings - 2.1% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 3.2.

Real-world access to riluzole 5 MG/ML Oral Suspension [Tiglutik] depends on utilization management as much as tier placement: 42.1% of covering formularies require prior authorization. 0% require step therapy. 5.3% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 9,582 Part D beneficiaries filled riluzole 5 MG/ML Oral Suspension [Tiglutik] in 2023, with total plan-and-beneficiary spending of $10,345,703 and an average per-beneficiary annual cost of $1,079.70. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry riluzole 5 MG/ML Oral Suspension [Tiglutik] today.